Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma

NCT02808091 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Slow recruitment

Conditions

Extranodal NK-T-CELL LYMPHOMA

Interventions

DRUG: GIFOX-Bortezomib
DRUG: GIFOX-Bortezomib
RADIATION: IMRT

Sponsor

National Cancer Centre, Singapore